Frequency Therapeutics (FREQ) Virtual R&D Event
Frequency Therapeutics (FREQ) will host a Virtual R&D Event for investors on Tuesday, November 9th from 8:00 am to 10:00 am EST. The program will include presentations by management, key opinion leaders and program executives who will provide detail on a broad range of pipeline advances for Frequency’s clinical-stage efforts in hearing restoration, plans for new FX-322 Phase 2 studies in sensorineural hearing loss, as well as its pre-clinical program for remyelination in multiple sclerosis.
Agenda (Partial)
- Program update for FX-322, a regenerative drug candidate to treat sensorineural hearing loss (SNHL)
- Detailed overview and insights from all data from clinical studies of FX-322
- Overview of ongoing FX-322 clinical development program and strategy
- Regulatory update and patient reported outcome measures
- Hearing research and discovery programs and opportunities for pipeline expansion
- Presentations by key opinion leaders
- Sumit Dhar, PhD, Hugh Knowles Professor of Hearing Science and Associate Provost for Faculty at Northwestern University
- Steven D. Targum, MD, Scientific Director, Signant Health
- Remyelination in multiple sclerosis
- Overview of Frequency’s program for remyelination in multiple sclerosis
- In vivo data and approach to target identification toward initiation of clinical trials
- Q&A with management and key opinion leaders
- David L. Lucchino, Chief Executive Officer
- Peter Pfreundschuh, Chief Financial Officer
- Carl LeBel, PhD, Chief Development Officer
- Christopher Loose, PhD, Chief Scientific Officer
- Kevin Franck, PhD, SVP, Strategic Marketing and New Product Planning
- Susan Stewart, JD, LLM, Chief Regulatory Officer
- Sanjay Magavi, PhD, VP, Myelination Research
- Robert S. Langer, ScD, Co-founder, Frequency Therapeutics and Institute Professor, Massachusetts Institute of Technology